Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2017:

Required1. Record any impairment losses at December 31, 2017. Assume Kane Biotech has recorded no impairment losses in previous years.2. Record depreciation for each asset at December 31, 2018. Assume that there was no change in the residual values or useful lives regardless of any impairment losses that might have occurred. The equipment produced 1,800 units during 2018.

Transcribed Image Text:

Asset Equipment Furniture Date of Purchase Land Office building Warehouse Deprec. Method* May 1/12 Jun. 28/12 Apr. 5/12 Apr. 5/12 Apr. 5/12 Cost $40,000 12,000 85,000 77,000 55,000 Units DDB N/A SL SL 7,000 units 8 yrs N/A 15 yrs 20 yrs *DDB = Double-declining-balance; SL = Straight-line; Units Units-of-production; N/A = Not applicable Residual Value = Useful Life $ 5,000 2,000 N/A 17,000 10,000 Accum. Deprec. $20,000 9,509 N/A 23,000 12,938 Recoverable Amount $ 8,000 2,950 101,800 52,500 45,100